Table 5 Pooled estimates for CRT reduction from baseline for PDT versus anti-VEGF
Outcome of interest | Studies (n) | WMD (95 % CI) | Test for Overall Effect | Study Heterogeneity | ||
|---|---|---|---|---|---|---|
χ2 | p | I2 | ||||
CRT Reduction (3mo) | ||||||
Design | ||||||
All trials | 5 | 18.69 (−0.83, 38.20) | Z =1.88, P =0.061 | 2.36 | 0.670 | 0.00 % |
Retro | 3 | 22.75 (−0.96, 44.54) | Z =1.05, P =0.141 | 1.56 | 0.459 | 0.00 % |
RCT | 2 | 2.24 (−41.62, 46.09) | Z =0.10, P =0.920 | 0.13 | 0.719 | 0.00 % |
Type of OCT | ||||||
TD-OCT | 3 | 10.47 (−30.90, 51.85) | Z =0.50, P =0.620 | 1.29 | 0.526 | 0.00 % |
SD-OCT | 2 | 21.03(−1.09, 43.17) | Z =1.86, P =0.062 | 0.88 | 0.348 | 0.00 % |
CRT Reduction (6mo) | ||||||
Design | ||||||
All trials | 4 | 44.94 (16.44, 73.44) | Z =3.09, P =0.002 | 4.30 | 0.231 | 30.3 % |
Retro | 2 | 36.87 (14.58, 59.16) | Z =3.24, P =0.001 | 0.65 | 0.421 | 0.00 % |
RCT | 2 | 66.62 (3.42, 129.81) | Z =2.07, P =0.039 | 2.05 | 0.152 | 51.3 % |
Type of OCT | ||||||
TD-OCT | 2 | 22.15 (2.98, 67.30) | Z =2.06, P =0.038 | 0.17 | 0.678 | 0.00 % |
SD-OCT | 2 | 62.13 (8.19, 116.07) | Z =2.26, P =0.024 | 3.08 | 0.079 | 67.5 % |
CRT Reduction (12mo) | ||||||
Design | ||||||
All trials | 3 | 13.91(−42.14, 69.97) | Z =0.49, P =0.627 | 8.48 | 0.014 | 76.4 % |
Retro | 2 | 36.03 (−13.52, 85.58) | Z =1.43, P =0.154 | 2.48 | 0.115 | 59.6 % |
RCT | 1 | 13.91 (−42.14, 69.97) | Z =1.00, P =0.315 | - | - | |
Type of OCT | ||||||
TD-OCT | 1 | 1.35 (−60.65, 63.35) | Z =0.04, P =0.966 | - | - | - |
SD-OCT | 2 | 16.70 (−65.61, 99.00) | Z =0.40, P =0.691 | 6.92 | 0.009 | 85.6 % |